Additional important safety considerations include risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia (when used with insulin or sulfonylureas), and potential effects on diabetic retinopathy
1 In an effort to minimize unnecessary disruptions to patient treatment, the FDA confirmed that it does not intend to take enforcement action against outsourcing facilities and compounders for violations of the Federal Food, Drug, and Cosmetic Act (FDCA) arising from conditions that depend on tirzepatide injection products inclusion on the FDAs drug shortage list, or for compounding, distributing, or dispensing tirzepatide injection products that are essentially a copy of Mounjaro and Zepbound, during the following periods: However, the FDA may still take action against these parties regarding violations of other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe for patients
By using Next Generation Sequencing (NGS) , it analyzes specific genetic regions to help identify potential health risks
Hyperkinesis (5%), hyporeflexia (2%), and grand mal seizures (1%) were reported in add-on epilepsy trials in pediatric patients
Across the PIONEER trials around 1523% of patients experienced nausea with orally administered semaglutide 14 mg, and approximately 715% of patients on 14 mg orally administered semaglutide discontinued the trial
When prescribed for this purpose Semaglutide is dispensed as Wegovy which is specifically licensed to aid weight loss